Investment Analysts’ Weekly Ratings Updates for Astrazeneca (AZN)

A number of firms have modified their ratings and price targets on shares of Astrazeneca (NYSE: AZN) recently:

• 10/13/2026 – Astrazeneca was upgraded by Nordea Equity Research from “sell” to “buy”.
• 10/13/2026 – Astrazeneca was upgraded by Zacks Research from “strong sell” to “hold”.
• 10/11/2026 – Astrazeneca was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/6/2026 – Astrazeneca had its “buy” rating reaffirmed by Citigroup Inc..
• 10/3/2026 – Astrazeneca was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/15/2026 – Astrazeneca was upgraded by Deutsche Bank Aktiengesellschaft from “sell” to “hold”.
• 9/14/2026 – Astrazeneca was downgraded by Zacks Research from “hold” to “strong sell”.
• 9/8/2026 – Astrazeneca is now covered by Royal Bank Of Canada. They set an “outperform” rating on the stock.
• 8/23/2026 – Astrazeneca is now covered by CICC Research. They set an “outperform” rating and a $198.00 price target on the stock.

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.